Testing novel drugs or drug combinations to treat breast cancer before surgery
Enrolling By Invitation
18-99 years
Female
Phase
N/A
1 Location
Brief description of study
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with
or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic
complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature
established at trial entry, and to determine for each experimental agent used, the predictive probability of
success in a subsequent phase 3 trial for each possible biomarker signature.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: Female
Females, Over 18, Newly diagnosed Breast Cancer
Updated on
01 Aug 2024.
Study ID: 844215
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com